Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Deferred Tax (2021 - 2026)

Bioventus filings provide 3 years of Long-Term Deferred Tax readings, the most recent being $4.7 million for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 35.84% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 35.84% decrease, with the full-year FY2024 number at $4.7 million, changed N/A from a year prior.
  • Long-Term Deferred Tax hit $4.7 million in Q3 2025 for Bioventus, roughly flat from $4.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $7.4 million in Q3 2024 to a low of $481000.0 in Q2 2021.
  • Median Long-Term Deferred Tax over the past 3 years was $4.7 million (2024), compared with a mean of $3.5 million.
  • The widest YoY moves for Long-Term Deferred Tax: up 31.07% in 2025, down 35.84% in 2025.
  • Bioventus' Long-Term Deferred Tax stood at $481000.0 in 2021, then skyrocketed by 886.49% to $4.7 million in 2024, then changed by 0.0% to $4.7 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $4.7 million (Q3 2025), $4.7 million (Q2 2025), and $4.7 million (Q1 2025) per Business Quant data.